235 related articles for article (PubMed ID: 2043699)
1. Tumor immunology.
Naftzger C; Houghton AN
Curr Opin Oncol; 1991 Feb; 3(1):93-9. PubMed ID: 2043699
[TBL] [Abstract][Full Text] [Related]
2. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral immune responses against cancer: implications for cancer vaccines.
Knuth A; Wölfel T; Meyer zum Büschenfelde KH
Curr Opin Immunol; 1991 Oct; 3(5):659-64. PubMed ID: 1755985
[TBL] [Abstract][Full Text] [Related]
4. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
Kourilsky P; Jaulin C; Ley V
Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
[TBL] [Abstract][Full Text] [Related]
5. Possibilities for active immunotherapy of human cancer.
Hellström KE; Hellström I
Cancer Invest; 1992; 10(4):285-93. PubMed ID: 1378351
[No Abstract] [Full Text] [Related]
6. Update on tumor vaccines.
Stevenson FK
Int J Clin Lab Res; 1992; 22(2):84-9. PubMed ID: 1504310
[TBL] [Abstract][Full Text] [Related]
7. An introduction to tumour immunology.
James K
Arch Immunol Ther Exp (Warsz); 1983; 31(6):795-808. PubMed ID: 6611141
[TBL] [Abstract][Full Text] [Related]
8. Oncogene-associated tumor antigens as targets for immunotherapy.
Hellström KE; Hellström I
FASEB J; 1989 Apr; 3(6):1715-22. PubMed ID: 2649402
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunology--when a cancer cell meets the immune cells.
Sheu BC; Hsu SM; Ho HN; Lin RH; Huang SC
J Formos Med Assoc; 1999 Nov; 98(11):730-5. PubMed ID: 10705688
[TBL] [Abstract][Full Text] [Related]
10. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
Gaugler B; Olive D
Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
[TBL] [Abstract][Full Text] [Related]
11. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
12. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
13. Immune privilege, tumors, and the eye.
Chen PW; Ksander BR
Chem Immunol; 1999; 73():137-58. PubMed ID: 10590578
[No Abstract] [Full Text] [Related]
14. Toward a genetic analysis of tumor rejection antigens.
Boon T
Adv Cancer Res; 1992; 58():177-210. PubMed ID: 1546558
[No Abstract] [Full Text] [Related]
15. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
Van den Eynde B
Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005
[TBL] [Abstract][Full Text] [Related]
16. [Immunology of tumors].
Clerici E
Minerva Nefrol; 1983; 30(2 Suppl):13-8. PubMed ID: 6866320
[No Abstract] [Full Text] [Related]
17. MHC gene control of the natural killer system at the level of the target and the host.
Kärre K
Semin Cancer Biol; 1991 Oct; 2(5):295-309. PubMed ID: 1773046
[TBL] [Abstract][Full Text] [Related]
18. p53: a potential target antigen for immunotherapy of cancer.
Offringa R; Vierboom MP; van der Burg SH; Erdile L; Melief CJ
Ann N Y Acad Sci; 2000 Jun; 910():223-33; discussion 233-6. PubMed ID: 10911916
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunology.
Stevenson H; Tsang KY
Immunol Ser; 1993; 58():497-515. PubMed ID: 8424991
[No Abstract] [Full Text] [Related]
20. Histocompatibility antigens on murine tumors.
Goodenow RS; Vogel JM; Linsk RL
Science; 1985 Nov; 230(4727):777-83. PubMed ID: 2997918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
